Clinical trials/post-approval
| Etanercept | Infliximab | Adalimumab | |
|---|---|---|---|
| *Includes psoriatic arthritis, juvenile rheumatoid arthritis; †Includes Aspire. | |||
| RA trials (No of patients) | 3839* | 1298† | 2468 |
| RA trials (patient-years exposure) | 8336 | 2458 | 4870 |
| Post-approval (number of patientsts) | >150000 | 198234 | NA |
| Post-approval (patient-years exposure) | >230000 | 227559 | NA |